

Simone Scagnoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9547780/publications.pdf>

Version: 2024-02-01

28
papers

494
citations

623734

14
h-index

713466

21
g-index

29
all docs

29
docs citations

29
times ranked

770
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant chemotherapy in resected colon cancer: When, how and how long?. <i>Surgical Oncology</i> , 2019, 30, 100-107.	1.6	58
2	Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	4.8	47
3	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
4	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	4.4	38
5	CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. <i>Cancers</i> , 2021, 13, 332.	3.7	35
6	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. <i>Targeted Oncology</i> , 2018, 13, 227-234.	3.6	33
7	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	4.8	30
8	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	2.5	28
9	The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119.	4.4	24
10	Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients. <i>Journal of Personalized Medicine</i> , 2020, 10, 208.	2.5	23
11	Immune effects of CDK4/6 inhibitors in patients with HR+/HER2 ⁻ metastatic breast cancer: Relief from immunosuppression is associated with clinical response. <i>EBioMedicine</i> , 2022, 79, 104010.	6.1	22
12	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	4.1	21
13	Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2620.	3.7	21
14	Burned-Out Testicular Cancer: Really a Different History. <i>Case Reports in Oncology</i> , 2018, 10, 846-850.	0.7	17
15	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	3.7	10
16	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	3.7	10
17	5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1836-1842.	0.9	8
18	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	3.2	6

#	ARTICLE	IF	CITATIONS
19	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
20	Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3067-3067.	1.6	4
21	P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP). <i>Journal of Thoracic Oncology</i> , 2017, 12, S1337-S1338.	1.1	3
22	Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103282.	4.4	3
23	Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3087-3087.	1.6	2
24	Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study. , 2020, , .		1
25	The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature. <i>Frontiers in Oncology</i> , 2022, 12, 797157.	2.8	1
26	Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 177-177.	1.6	0
27	Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15158-e15158.	1.6	0
28	Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report. <i>AboutOpen</i> , 2018, 4, 185-190.	0.2	0